References
- 1. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer, 127(12), 2893-2917.
- 2. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. & Forman, D. (2011). Global cancer statistics. CA: a cancer journal for clinicians, 61(2), 69-90.10.3322/caac.20107
- 3. Powell, H.A. & Baldwin, D.R. (2014). Multidisciplinary team management in thoracic oncology: more than just a concept? Eur Respir J, 43(6), 1776-1786. doi: 10.1183/09031936.00150813
- 4. Detterbeck, F. C., Boffa, D. J., Kim, A. W., & Tanoue, L. T. (2017). The Eighth Edition Lung Cancer Stage Classification. CHEST Journal, 151(1), 193-203..
- 5. Goldstraw, P., Chansky, K., Crowley, J., Rami- Porta, R., Asamura, H., Eberhardt, W. E., ... & Rami-Porta, R. (2016). The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. Journal of Thoracic Oncology, 11(1), 39-51.10.1016/j.jtho.2015.09.009
- 6. Lindeman, N.I., Cagle, P.T., Beasley, M.B., Chitale, D.A., Dacic, S., Giaccone, G., Jenkins, R.B., Kwiatkowski, D.J., Saldivar , J.S., Squire, J., Thunnissen, E. & Ladanyi, M. (2013). Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 137(6), 828-60. doi: 10.5858/arpa.2012-0720-OA.
- 7. Lista protocoalelor terapeutice cu modificarile si completarile ulterioare. (2017). Retrieved from http://www.cnas.ro/
- 8. Kris, M.G., Johnson, B.E., Berry, L.D., Kwiatkowski, D.J., Iafrate, A.J., Wistuba, I.I., Varella-Garcia, M., Franklin, W.A., Aronson, S.L. & Su, P.-F. (2014). Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. Jama, 311(19), 1998-2006. doi: 10.1001/jama.2014.3741.
- 9. Diaz Jr, L.A. & Bardelli, A. (2014). Liquid biopsies: genotyping circulating tumor DNA. Journal of clinical oncology, 32(6), 579-586. .
- 10. Sequist, L.V., Neal, W.N. (2017). Personalized, genotype-directed therapy for advanced nonsmall cell lung cancer. UpToDate 2017
- 11. Kerr, K.M., Bubendorf, L., Edelman, M.J., Marchetti, A., Mok, T., Novello, S., O'Byrne, K., Stahel, R., Peters, S. & Felip, E. (2014). Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 25(9), 1681-1690. doi: 10.1093/annonc/mdu145
- 12. Leighl, N.B., Rekhtman, N., Biermann, W.A., Huang, J., Mino-Kenudson, M., Ramalingam, S.S., West, H., Whitlock, S. & Somerfield, M.R. (2014). Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. Journal of clinical oncology, 32(32), 3673-3679.
- 13. Oxnard, G.R., Thress, K.S., Alden, R.S., Lawrance, R., Paweletz, C.P., Cantarini, M., Yang, J.C.-H., Barrett, J.C. & Jänne, P.A. (2016). Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. Journal of clinical oncology, 34(28), 3375-3382.